Company intelligence / Profile preview

Elise Biopharma

Seongnam-si, Gyeonggi-do, South Koreaelisebio.com ↗

Ownership: Private
Development stage: Other

Overview

Elise Biopharma is a South Korean biotechnology company focused on the discovery and development of novel small molecule therapeutics for oncology and inflammatory diseases. Founded in 2020 by Dr. Seong-Jin Kim, a pioneer in TGF-beta research, the company leverages deep expertise in signaling pathways to target the tumor microenvironment. Its lead program, EB-101, is a selective TGF-beta inhibitor aimed at overcoming resistance to immune checkpoint inhibitors in solid tumors. The company utilizes a proprietary drug discovery platform to identify high-potency candidates with optimized safety profiles. Elise Biopharma is currently advancing its pipeline through pre-clinical development with the goal of entering clinical trials.

Therapeutic areas: ImmunologyOtherOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Elise Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elise Biopharma.